Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Taveira-DaSilva AM, Moss J.

Expert Opin Orphan Drugs. 2016;4(4):369-378. Epub 2016 Mar 7.

2.

Lymphangioleiomyomatosis.

Taveira-DaSilva AM, Steagall WK, Moss J.

Atlas Genet Cytogenet Oncol Haematol. 2009;13(10):751-757. No abstract available.

3.

Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis.

Clements D, Dongre A, Krymskaya VP, Johnson SR.

PLoS One. 2015 May 15;10(5):e0126025. doi: 10.1371/journal.pone.0126025. eCollection 2015.

4.

Antibody ╬▒PEP13h reacts with lymphangioleiomyomatosis cells in lung nodules.

Valencia JC, Steagall WK, Zhang Y, Fetsch P, Abati A, Tsukada K, Billings E, Hearing VJ, Yu ZX, Pacheco-Rodriguez G, Moss J.

Chest. 2015 Mar;147(3):771-777. doi: 10.1378/chest.14-0380.

5.

Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.

Li C, Zhang E, Sun Y, Lee PS, Zhan Y, Guo Y, Osorio JC, Rosas IO, Xu KF, Kwiatkowski DJ, Yu JJ.

PLoS One. 2014 Oct 27;9(10):e104809. doi: 10.1371/journal.pone.0104809. eCollection 2014.

6.

Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.

Cai X, Pacheco-Rodriguez G, Haughey M, Samsel L, Xu S, Wu HP, McCoy JP, Stylianou M, Darling TN, Moss J.

Chest. 2014 Jan;145(1):108-112. doi: 10.1378/chest.13-1071.

7.

Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Steagall WK, Pacheco-Rodriguez G, Glasgow CG, Ikeda Y, Lin JP, Zheng G, Moss J.

Am J Pathol. 2013 Sep;183(3):938-50. doi: 10.1016/j.ajpath.2013.05.024. Epub 2013 Jul 16.

8.

Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis.

Glasgow CG, El-Chemaly S, Moss J.

Eur Respir Rev. 2012 Sep 1;21(125):196-206. doi: 10.1183/09059180.00009311. Review.

9.

Optimizing treatments for lymphangioleiomyomatosis.

Taveira-DaSilva AM, Moss J.

Expert Rev Respir Med. 2012 Jun;6(3):267-76. doi: 10.1586/ers.12.26. Review.

10.

Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2.

Ikeda Y, Taveira-DaSilva AM, Pacheco-Rodriguez G, Steagall WK, El-Chemaly S, Gochuico BR, May RM, Hathaway OM, Li S, Wang JA, Darling TN, Stylianou M, Moss J.

Am J Physiol Lung Cell Mol Physiol. 2011 Jan;300(1):L64-72. doi: 10.1152/ajplung.00095.2010. Epub 2010 Oct 29.

11.

The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells.

Pacheco-Rodriguez G, Moss J.

Crit Rev Immunol. 2010;30(4):387-94. Review.

12.

Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis.

Cai X, Pacheco-Rodriguez G, Fan QY, Haughey M, Samsel L, El-Chemaly S, Wu HP, McCoy JP, Steagall WK, Lin JP, Darling TN, Moss J.

Am J Respir Crit Care Med. 2010 Dec 1;182(11):1410-8. doi: 10.1164/rccm.201003-0489OC. Epub 2010 Jul 16.

13.

Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.

Glasgow CG, Steagall WK, Taveira-Dasilva A, Pacheco-Rodriguez G, Cai X, El-Chemaly S, Moses M, Darling T, Moss J.

Respir Med. 2010 Jul;104 Suppl 1:S45-58. doi: 10.1016/j.rmed.2010.03.017.

14.

Lymphangioleiomyomatosis and TSC2-/- cells.

Darling TN, Pacheco-Rodriguez G, Gorio A, Lesma E, Walker C, Moss J.

Lymphat Res Biol. 2010 Mar;8(1):59-69. doi: 10.1089/lrb.2009.0031. Review.

15.
16.

The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Taveira-DaSilva AM, Pacheco-Rodriguez G, Moss J.

Lymphat Res Biol. 2010 Mar;8(1):9-19. doi: 10.1089/lrb.2009.0024.

17.

A National Heart, Lung, and Blood Institute history and perspective on lymphangioleiomyomatosis.

Peavy H, Gail D, Kiley J, Shurin S.

Lymphat Res Biol. 2010 Mar;8(1):5-8. doi: 10.1089/lrb.2009.0023. No abstract available.

18.

Involvement of lymphatics in lymphangioleiomyomatosis.

Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G, Steagall WK, Tsukada K, Cai X, El-Chemaly S, Moss J.

Lymphat Res Biol. 2009 Dec;7(4):221-8. doi: 10.1089/lrb.2009.0017.

19.

The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.

Lesma E, Sirchia SM, Ancona S, Carelli S, Bosari S, Ghelma F, Montanari E, Di Giulio AM, Gorio A.

Am J Pathol. 2009 Jun;174(6):2150-9. doi: 10.2353/ajpath.2009.080799. Epub 2009 May 14.

20.

Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

Glasgow CG, Avila NA, Lin JP, Stylianou MP, Moss J.

Chest. 2009 May;135(5):1293-1300. doi: 10.1378/chest.08-1160.

Supplemental Content

Support Center